Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncolog
Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage
The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious disp
At DPHARM 2023 in Boston, Pfizer announced that it has taken the first steps towards sharing clinical trial participants’ own data with them – something participants have sought for years.<
Already a mainstay of prostate cancer therapy, Pfizer and Astellas’ Xtandi has picked up a new approval in the US that could reinvigorate the drug, even as it approaches i
